Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

The 10 most innovative biotech companies of 2025 are leveraging AI to find new drugs, match patients with the best treatments ...

The firm is using single-cell, multiomics analysis to probe tumor samples from very long-term cancer survivors for keys to defeat the disease.

Background: Wilms tumor (WT) is the most common childhood renal malignancy, with recurrence linked to poor prognosis. Identifying the molecular features of tumor phenotypes that drive recurrence and ...

Trisha Bartlett is an Associate Director of Strategic Marketing at 10x Genomics, supporting the Visium and Xenium spatial platforms. She leads marketing efforts for customers across academic and ...

It features a software stock we’re confident has 10X potential. Road sign showing a fork in the road Philip Panaro is the founder and former CEO of Boston Consulting Group who clearly remains ...

As the Uniswap price fluctuates, investors are eyeing DeFi tokens for 10x gains in 2025. Remittix, Near Protocol, Uniswap, and Aave stand out as top contenders. Let us highlight each top altcoins ...

However, only $17.5 billion, less than half, represents genuine long-only buying, reported 10x Research head of research Markus Thielen. The majority, or around 56%, “is likely tied to arbitrage ...